ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Phase 1
Recruiting
- Conditions
- Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-505530-10-00
- Lead Sponsor
- Janssen - Cilag International
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 365
Inclusion Criteria
All subjects who received cilta-cel in a Company-sponsored clinical study are candidates for Study MMY4002. The inclusion criteria for the study are described below: 1. Subjects who have received at least one dose of cilta-cel in a Company-sponsored clinical study., 2. Subjects who have provided informed consent for Study MMY4002.
Exclusion Criteria
No exclusion criteria are applicable in this study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method